Pharma major Lupin announced that it has received approval for its Tadalafil Tablets USP, 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company’s Adcirca Tablets, 20 mg.

Lupin’s Tadalafil Tablets USP, 20 mg is the generic version of Eli Lilly and Company’s Adcirca Tablets, 20 mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

Tadalafil Tablets, 20 mg (RLD: Adcirca) had annual sales of approximately USD 474.3 million in the US (IQVIA MAT December 2018).

Shares of the company declined Rs 22.35, or 2.65%, to trade at Rs 819.60. The total volume of shares traded was 143,872 at the BSE (11.14 a.m., Thursday).